Colorectal Cancer News and Research RSS Feed - Colorectal Cancer News and Research

Colorectal Cancer is cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus). In the United States, it is the fourth most common cancer in men and women. Caught early, it is often curable.
Study provides better understanding of sequence of genetic events in colorectal cancer premalignancy

Study provides better understanding of sequence of genetic events in colorectal cancer premalignancy

Whole-exome sequencing of both colorectal adenomas (precancers often called polyps) and intestinal mucosa at risk for developing into adenomas from patients with familial adenomatous polyposis (FAP) has generated a comprehensive picture of the genomic alterations that characterize the evolution of normal mucosa to precancer. [More]
Mitoxantrone for MS linked to colorectal cancer risk

Mitoxantrone for MS linked to colorectal cancer risk

Treatment with mitoxantrone for multiple sclerosis carries only a mildly increased risk of malignancy overall, but the risk of colorectal cancer and leukaemia is heightened, researchers have found. [More]
Study shows endoscopist knowledge of positive Cologuard result may enhance colonoscopy quality

Study shows endoscopist knowledge of positive Cologuard result may enhance colonoscopy quality

An endoscopist's knowledge of a positive Cologuard test improves colonoscopy performance, according to a poster presentation at last week's Digestive Disease Week conference. [More]
Researchers identify mutations that may stimulate early cancer growth in precancerous colorectal tissue

Researchers identify mutations that may stimulate early cancer growth in precancerous colorectal tissue

Researchers at The University of Texas MD Anderson Cancer Center have discovered mutations that may fuel early cancer growth in precancerous colorectal tissue from high-risk patients. [More]
Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial. [More]
Could a new test improve bowel cancer screening uptake? An interview with Professor Halloran

Could a new test improve bowel cancer screening uptake? An interview with Professor Halloran

The most recent complete data for England (2014/15) shows an average uptake of the guaiac Faecal Occult Blood Tests (gFOBT) from those invited by the NHS Bowel Cancer Screening Programme (BCSP) of 58.22%. [More]
Diet experiments on Lynch syndrome mouse model may help in early detection of colon cancer

Diet experiments on Lynch syndrome mouse model may help in early detection of colon cancer

Colorectal cancer is the second most common cause of cancer-related deaths in the Western world, mainly because it is usually diagnosed too late. Finding ways to identify those people who are at increased risk of developing colon cancer is therefore crucial, a researcher will tell the annual conference of the European Society of Human Genetics today. [More]
Targeting ERK and compensatory pathways with drug inhibitors halts colorectal cancer growth

Targeting ERK and compensatory pathways with drug inhibitors halts colorectal cancer growth

While investigating a potential therapeutic target for the ERK1 and 2 pathway, a widely expressed signaling molecule known to drive cancer growth in one third of patients with colorectal cancer, University of California San Diego School of Medicine researchers found that an alternative pathway immediately emerges when ERK1/2 is halted, thus allowing tumor cell proliferation to continue. [More]
New research solves mystery of why cetuximab drug proved futile for many colorectal cancer patients

New research solves mystery of why cetuximab drug proved futile for many colorectal cancer patients

Cancer researchers have identified a marker that shows up in a blood test that determines which patients with colorectal cancer that has spread would benefit from receiving the drug cetuximab. [More]
Depressed cancer patients less likely to recover well after treatment

Depressed cancer patients less likely to recover well after treatment

People with depression are significantly less likely to recover well after treatment for colorectal cancer compared to those without depression, according to new research by Macmillan Cancer Support and the University of Southampton. [More]
Mitoxantrone drug users more likely to develop colorectal cancer

Mitoxantrone drug users more likely to develop colorectal cancer

The multiple sclerosis (MS) drug mitoxantrone may be associated with an increased risk of colorectal cancer, according to a study published in the May 11, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology. Mitoxantrone suppresses the immune system. [More]
Medicare policy puts low-income Americans at increased risk for colorectal cancer

Medicare policy puts low-income Americans at increased risk for colorectal cancer

Colorectal cancer is the second highest cause of cancer death in the United States, expected to claim the lives of an estimated 49,190 people in 2016. The Affordable Care Act aimed to increase access to CRC screening by not holding patients responsible for all costs of the procedure, yet current Medicare insurance beneficiaries lacking supplemental insurance may not be able to afford colon cancer screening and treatment. [More]
Oophorectomy could increase colorectal cancer risk in both pre- and postmenopausal women

Oophorectomy could increase colorectal cancer risk in both pre- and postmenopausal women

Colorectal cancer may rise in women who have their ovaries removed, according to new research. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
ATR-FTIR spectroscopy could be effective for detecting ulcerative colitis

ATR-FTIR spectroscopy could be effective for detecting ulcerative colitis

A minimally invasive screening for ulcerative colitis, a debilitating gastrointestinal tract disorder, using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body, according to researchers at Georgia State University. [More]
Cholesterol-lowering drugs may not reduce colorectal cancer risk

Cholesterol-lowering drugs may not reduce colorectal cancer risk

Long-term use of the cholesterol-lowering drugs known as statins does not appear to decrease a patient's risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine researchers published this week in PLOS Medicine. [More]
Study shows safety of experimental drug guadecitabine in colorectal cancer patients

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI-110) is safe in combination with the chemotherapy drug irinotecan and may overcome resistance to irinotecan in patients with metastatic colorectal cancer. [More]
Flat adenomas may warrant keeping closer eye on patients at risk for colorectal cancer

Flat adenomas may warrant keeping closer eye on patients at risk for colorectal cancer

Being on the lookout for certain features of polyps may help physicians keep a closer eye on patients at risk for colorectal cancer. [More]
Epigenomics receives FDA approval for Epi proColon®

Epigenomics receives FDA approval for Epi proColon®

Epigenomics AG, the German-American cancer molecular diagnostics company, has announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s lead product, Epi proColon®, the first and only FDA-approved blood-based colorectal cancer screening test. [More]
Moffitt study reports that liver metastases have different sensitivities to radiation therapy

Moffitt study reports that liver metastases have different sensitivities to radiation therapy

Radiation is a commonly used therapeutic option to treat liver metastases, with the majority of tumors maintained under control after one year. However, some patients do not respond as well to radiation treatment, and the factors that predict patient outcomes are unclear. Moffitt Cancer Center researchers report that liver metastases have different sensitivities to radiation therapy based on the location of the primary tumor. [More]
Advertisement